Meeting
2014 ASCO Annual Meeting
Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.
Authors
Mehrdad Mobasher
Genentech, Inc., South San Francisco, CA
Mehrdad Mobasher , Jane Huang , Rebecca L. Elstrom , Mostafa Elhamy , Coen Bernaards , Michael J. Hallek , Peter Hillmen , Arnon Philip Kater , Thomas J. Kipps , John Francis Seymour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT02005471
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7120^)
DOI
10.1200/jco.2014.32.15_suppl.tps7120
Abstract #
TPS7120^
Poster Bd #
404B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).
First Author: Jason Westin
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).
First Author: Martin H. Dreyling
Poster
2018 ASCO Annual Meeting
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
First Author: Saad Zafar Usmani
Poster
2017 ASCO Annual Meeting
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Robert W. Chen